Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Taking a GLP-1 may help treat sleep apnea since obesity is one of many factors that increases your likelihood of the sleep ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Time for your weekly edition of the Defector Funbag. Got something on your mind? Email the Funbag. And buy Drew’s book, The ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...